Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer

20261 citationsJournal Articlegreen Open Access

Authors

Frank A. Sinicrope · Mayo Clinic in Arizona

Fang‐Shu Ou · Mayo Clinic

Dirk Arnold · Asklepios Klinik Altona

Walter R. Peters · Baylor University Medical Center

Robert J. Behrens · Iowa Oncology Research Association

Christopher H. Lieu · University of Colorado Cancer Center

Khalid Matin

Abstract

The addition of atezolizumab to mFOLFOX6 significantly improved disease-free survival among patients with stage III dMMR colon cancer. (Funded by the National Cancer Institute of the National Institutes of Health and Genentech; ATOMIC ClinicalTrials.gov number, NCT02912559.).

Topics & Keywords

Genetic factors in colorectal cancer Colorectal Cancer Treatments and Studies Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: New England Journal of Medicine

Volume 394, Issue 12, pp. 1155-1166

DOI: 10.1056/nejmoa2507874

Field-Weighted Citation Impact: 36.00